More importantly, they show that reducing RUNX1 transcriptional activity may be an opportunity to improve the sensitivity of CSC/CTC to chemotherapy leading to a potential reduction in metastasis or tumor recurrence in AR+-TNBC. This evidence concerns the gene RUNX1 and neoplasm.